Given that Kurmann et al. (37) only looked at all SSc patients (without stratifying by CRP−positivity) and that our reported ASCVD risk for the CRP+ SSc patient group ranged with a mean risk of 15% even significantly above Kurmann’s SSc patient cohort ASCVD risk, it seems very likely that the significant relationship between prolonged CRP−positivity and 10-year arteriosclerotic-cardiovascular risk observed in our study may even be underestimated. The gene discussed is CRP; the disease is systemic sclerosis.